Current Research Studies
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients
SAT-3247_201_Amb
What is the goal of the study?
This study will investigate safety and pharmacokinetics in a pediatric ambulatory population and aim to establish proof of concept as well as compare two doses (60 mg and 120 mg) of SAT-3247against placebo in 12 weeks of blinded treatment.
Who can participate in the study?
Please contact the study team listed below to learn more.